News
LTUS
0.0035
NaN%
--
*Alvogen Will Become a Controlled Subsidiary of Lotus
Dow Jones · 09/23 18:39
*Alvogen Announces Sale to Lotus, Creating a Leading Intl Specialized Generics Platform
Dow Jones · 09/23 18:39
Weekly Report: what happened at LTUS last week (0908-0912)?
Weekly Report · 09/15 09:31
Weekly Report: what happened at LTUS last week (0901-0905)?
Weekly Report · 09/08 09:32
Weekly Report: what happened at LTUS last week (0825-0829)?
Weekly Report · 09/01 09:30
Weekly Report: what happened at LTUS last week (0818-0822)?
Weekly Report · 08/25 09:33
Weekly Report: what happened at LTUS last week (0811-0815)?
Weekly Report · 08/18 09:31
Weekly Report: what happened at LTUS last week (0804-0808)?
Weekly Report · 08/11 09:32
Weekly Report: what happened at LTUS last week (0728-0801)?
Weekly Report · 08/04 09:34
Weekly Report: what happened at LTUS last week (0721-0725)?
Weekly Report · 07/28 09:34
Weekly Report: what happened at LTUS last week (0714-0718)?
Weekly Report · 07/21 09:32
Weekly Report: what happened at LTUS last week (0707-0711)?
Weekly Report · 07/14 09:33
Weekly Report: what happened at LTUS last week (0630-0704)?
Weekly Report · 07/07 09:32
Weekly Report: what happened at LTUS last week (0623-0627)?
Weekly Report · 06/30 09:33
Weekly Report: what happened at LTUS last week (0616-0620)?
Weekly Report · 06/23 09:31
Weekly Report: what happened at LTUS last week (0609-0613)?
Weekly Report · 06/16 09:33
Weekly Report: what happened at LTUS last week (0602-0606)?
Weekly Report · 06/09 09:33
Weekly Report: what happened at LTUS last week (0526-0530)?
Weekly Report · 06/02 09:36
Weekly Report: what happened at LTUS last week (0519-0523)?
Weekly Report · 05/26 09:35
Weekly Report: what happened at LTUS last week (0512-0516)?
Weekly Report · 05/19 09:33
More
Webull provides a variety of real-time LTUS stock news. You can receive the latest news about Lotus Pharma through multiple platforms. This information may help you make smarter investment decisions.
About LTUS
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.